Few events disrupt clinical development more than receiving a Form FDA 483 or a Warning Letter. These findings can erode trust with regulators, jeopardize ongoing trials, and threaten future approvals. The response must be fast enough to meet deadlines and strong enough to show that problems are understood and under control. Regulators expect a clear explanation of what went wrong, how widespread the issues are, and what will be done to prevent recurrence. Many organizations struggle to meet this standard while under intense time pressure and internal scrutiny.
HIC helps sponsors navigate these high stakes moments with clarity and discipline. Former FDA compliance officials and senior clinical leaders work with your team to interpret inspection findings, perform rigorous root cause analysis, and design corrective and preventive action plans that reach across studies, sites, and vendors. We craft responses that are specific, evidence based, and aligned with current regulatory expectations, including realistic timelines and measures of effectiveness. The aim is not only to close out the 483 or Warning Letter, but to strengthen your underlying quality system and protect the future of your development program.
Responses that restore regulator confidence
- Our team includes former FDA officials who have evaluated and negotiated 483 and Warning Letter responses across multiple inspection types
- We lead structured root cause analysis and define CAPA plans that address systemic issues across studies, sites, and vendors rather than treating symptoms
- Our experts draft response letters that are clear, logically organized, and supported by documentation that demonstrates accountability and sustained remediation
- We coach organizations on how to communicate with regulators during and after the response process, helping rebuild trust and reduce the risk of escalation
